Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Nantong Changyou Pharmaceutical Technology, obtained approval from China's National Medical Products Administration to produce and market active pharmaceutical ingredient Vericiguat, according to a Shanghai Stock Exchange filing on Tuesday.
Vericiguat, which was originally developed by global pharmaceutical giant Merck Sharp & Dohme, is primarily indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction, who have been stabilized following recent decompensated heart failure treated intravenously.
The Chinese pharma company invested 3.6 million yuan into the research and development of the API, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。